Comparison of On-hours Versus Off-hours Anesthesia of Hip Surgery
Comparison of Anesthesia Beginning at On-hours Versus Off-hours on Outcomes in Patients Undergoing Hip Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients who had hip surgery between January 1, 2015, and December 31, 2020 in Tongji Hospital.
Exclusion Criteria:
- under 18 years old
- had incomplete perioperative data
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
on-hours
Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as "on-hours".
|
If the begin time of anesthesia was between 8:00 to 17:59, it was defined as "on-hours".
|
|
off-hours
Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as "off-hours".
Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as "off-hours".
|
If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as "off-hours".
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
in-hospital mortality
Time Frame: up to 7 months
|
the mortality during hospitalization
|
up to 7 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative LOS
Time Frame: up to 4 months postoperatively
|
postoperative hospital length of stay
|
up to 4 months postoperatively
|
|
total LOS
Time Frame: up to 7 months
|
total hospital length of stay
|
up to 7 months
|
|
ICU admission
Time Frame: within 3 days postoperatively
|
the ratio of ICU admission
|
within 3 days postoperatively
|
|
postoperative complications
Time Frame: within 3 days postoperatively
|
including renal dysfunction, anemia, hypotension, deep vein thrombosis, arrhythmia, coronary artery disease or heart failure, pulmonary infection, electrolyte disturbance, hyoxemia and delirium
|
within 3 days postoperatively
|
|
intraoperative fluid management
Time Frame: intraoperative
|
including blood loss, urine volume, concentrated red blood cells, fresh frozen plasma, equilibrium liquid and colloidal solution
|
intraoperative
|
|
intraoperative sufentanil
Time Frame: intraoperative
|
the dosage of intraoperative sufentanil
|
intraoperative
|
|
using vasoactive drugs
Time Frame: intraoperative
|
whether using vasoactive drugs or not intraoperatively
|
intraoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wei Mei, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- TJ-IRB20210305
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.